Abstract: A method of rapidly inducing large-scale and high-purity mesenchymal stem cells to transdetermine into hematopoietic stem cells is provided with the steps of preparing homogeneous medium of mesenchymal stem cells; combining a plurality of small RNA molecules; assembling and transfecting nanoparticles of nucleic acids and polypeptides; inducing and amplifying medium of post-transdetermined hematopoietic stem cells; and activating a plurality of hemopoiesis-related genes.

Abstract: A kit of medium of inducing and amplifying hematopoietic stem cells, the kit includes medium of inducing and amplifying hematopoietic stem cell, and the medium of inducing and amplifying hematopoietic stem cell includes cell proliferation factors and cell differentiation inhibitors needed in proliferation of hematopoietic stem cells, and the formula of the medium of inducing and amplifying hematopoietic stem cell is: 80-100% (v/v) DMEM/F12 basic medium, 0-1 ?g/ml Sonic hedgehog, 0-1 ?g/ml Delta1, 0-1 ?g/ml Flt3L, 0-1 ?g/ml IGFBP, 0-1 ?g/ml SCF, 0-1 ?g/ml, Angiopoietin, 0-1 ?g/ml TPO, 0-1 ?g/ml MBP, 0-1 ?g/ml LIF, 0-1 ?g/ml TGF-?, 0-100 mM MTEPA, and 1-5 mM NAC.

Abstract: A method of rapidly inducing large-scale and high-purity mesenchymal stem cells to transdetermine into hematopoietic stem cells is provided with the steps of preparing homogeneous medium of mesenchymal stem cells; combining a plurality of small RNA molecules; assembling and transfecting nanoparticles of nucleic acids and polypeptides; inducing and amplifying medium of post-transdetermined hematopoietic stem cells; and activating a plurality of hemopoiesis-related genes.

Abstract: The present invention provides methods for designing and selecting efficacious SDSOs as a gene drug that can specifically inactivate a group of corresponding genes. In particular, this invention relates to a process including the recruitment of target genes causing a disease, the identification of an endogenous siRNA sequence, the prediction of an efficacious SDSO, and the assembly of one or more SDSOs into related carriers with the ability targeting to diseased a cell or a tissue. This invention further includes pharmaceutical compounds of a gene drug, particularly one or more 21 nt double-stranded oligonucleotides with a 5′-AU(T)CCG-3′ or 5′-U(T)CCCG-3′ cleavage pattern in its antisense strand, which can specifically hybridize with a 5′-CGGAU(T)-3′ or 5′-CGGGA-3′ motif in a or more cognate RNA molecules such as a primary transcript or an mRNA.